Trial Profile
A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Planned End Date changed from 31 Oct 2018 to 30 Sep 2026.
- 03 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.